genetics	ARCHIVE SEARCH INFORMATION CLASSIFIED
SUBSCRIBE	Supplementary Information
	Cadmium is a mutagen that acts by inhibiting mismatch repair
	Y H Jin, A B Clark, R J C Slebos, H Al-Refai, J A Taylor, T A Kunkel, M A Resnick & D A Gordenin Published online: 8 June 2003, doi:10.1038/ng1172 <u>Abstract</u> <u>Full text</u> <u>PDF</u> (363 K)
	ng1172-S1.pdf PDF file (384K)
	Supplementary Fig. 1
	ng1172-S2.pdf PDF file (352K)
	Supplementary Fig. 2
	ng1172-S3.pdf PDF file (288K)
Download Plugins	Supplementary Table 1
	ng1172-S4.pdf PDF file (96K)
	Supplementary Table 2
	ng1172-S5.pdf PDF file (64K)
	Supplementary Table 3
	ng1172-S6.pdf PDF file (96K)
	Supplementary Table 4
	ng1172-S7.pdf PDF file (128K)
	Supplementary Methods
	ng1172-S8.pdf PDF file (96K)
	Supplementary Note

Supplementary Note A.

MATERIALS AND METHODS

Yeast strains. Most of the yeast strains were isogenic with CG379¹ (Note CG379 the same as AMY125 in²). Each strain was $MAT\alpha$ ade5-1 his7-2 leu2-3,112 trp1-289 ura3-52. The *his*7-2 is a -1 frameshift mutation creating a run of 7 adenines, which reverts primarily by +1 changes³. The strains also carried mutant *lys2* alleles which were used as mutation or recombination reporters: (i) frameshift reporters -- long homonucleotide runs described in⁴ -- $lys_{2-A_{14}}$ (A14 run, reverts via -1), $lys_{2-A_{12}}$ (A12 run, reverts via +1), *lys2-A*₁₀ (A10 run, reverts via -1); (ii) interchromosomal recombination strains ALE100 and ALE101 and intrachromosomal ALE1000 and ALE1001 recombination strains are described in⁵. Strains carried 5'-truncated lys2 sequence and the LEU2 gene that were integrated into the same chromosome II as a direct repeat with the *lys2::HS-D* allele (intrachromosomal reporter) or into the chromosome III next to natural LEU2 gene (interchromosomal reporter). Four isogenic strains that differed in genetic background from CG379 were obtained from Dr. Sue Jinks-Robertson (SJR-strains in Fig. 2 and Supplementary Table 2). Each of these strains carried a homonucleotide run of 10 nucleotides, A, T, G or C, at the same position in the LYS2 gene⁶. The Pol δ proofreading-deficient mutant strains (*pol3-01*) have been described^{7,8}. Proofreadingdeficient Pol ε (*pol2-4*) strains in our collection appeared to be slightly more resistant to cadmium compared with all other isogenic strains. Therefore, we obtained fresh pol2-4 isolates using the replacing construct described in¹. Fresh *pol2-4* isolates were indistinguishable from all other isogenic strains, therefore we explain increased resistance phenomenon by acquiring a secondary mutation. Deletion-replacement isolates of

1

MMR-genes and other genes were created by transferring G418-resistance cassette (G418-R) from strains that were included in the complete set of haploid deletion strains purchased from ResGen Invitrogen Corporation

(http://www.resgen.com/products/YEASTD.php3). We used the deletion set based on BY4741 (*MATa his3-D1 leu2-D0 met15-D0 ura3-D0*). G418-R was amplified from genomic DNA of corresponding deletion strain with PCR primers homologous to intergenic regions 100-300 nt upstream and downstream the replaced ORF. PCR products carrying G418-R flanked by 100-300 regions surrounding the targeted ORF were used to transform wild type yeast strains to G418-resistance. The transformants arose primarily by homologous recombination replacing, the targeted ORF with the G418-R. The resulting deletions were verified by PCR and by phenotype. The sequences of the PCR primers are available upon request. Two independent isolates of each mutant were used in the study. Isogenic diploids were obtained by transforming haploid yeast strains with the plasmid YEpHO (carrying *LEU2* and HO-endonuclease). HO-endonuclease caused mating type switching within the cell population followed by mating and diploid formation.

A spot-test for mutagenesis in yeast A14 homonucleotide run (*lys2-A14*) was used to detect strong mutagenic effects. Approximately 10^8 yeast cells were plated onto 100 mm plates with synthetic complete (SC) or, in the case of exposure to FeCl₃, with YPD medium. A 24 mm filter paper circle was placed at the center and 200 µl of the test-solution was applied to the filter. Plates were incubated at 30° C for 3-4 days. The concentration of the agent that caused growth inhibition in the vicinity (5-10 mm) of the

2

filter circle, but allowed normal growth at larger distance was chosen for mutagenesis testing. (Note: in the case of 500 mM solutions of MnCl₂ and ZnSO₄, growth inhibition was barely detectable only in the close vicinity of the disk). These plates were replica plated to media without lysine. After 4-5 days plates with selective media were scored and responses were documented by scanning and storing photo-images. The appearance of increased density of revertant colonies compared with control was indicative of mutagenesis. Spot-tests were repeated 3-4 times for each chemical.

References for Supplementary Note A.

- Morrison, A., Bell, J. B., Kunkel, T. A. & Sugino, A. Eukaryotic DNA polymerase amino acid sequence required for 3'->5' exonuclease activity. *Proc. Natl. Acad. Sci. USA* 88, 9473-9477 (1991).
- Strand, M., Prolla, T. A., Liskay, R. M. & Petes, T. D. Destabilization of tracts of simple repetitive DNA in yeast by mutations affecting DNA mismatch repair. *Nature* 365, 274-276 (1993).
- Shcherbakova, P. V. & Kunkel, T. A. Mutator phenotypes conferred by *MLH1* overexpression and by heterozygosity for *mlh1* mutations. *Mol. Cell. Biol.* 19, 3177-3183. (1999).
- Tran, H. T., Keen, J. D., Kricker, M., Resnick, M. A. & Gordenin, D. A. Hypermutability of homonucleotide runs in mismatch repair and DNA polymerase proofreading yeast mutants. *Mol. Cell. Biol.* 17, 2859-2865 (1997).
- 5. Jin, Y. H. et al. The 3'-->5' exonuclease of DNA polymerase delta can substitute for the 5' flap endonuclease *Rad27/Fen1* in processing Okazaki fragments and

preventing genome instability. Proc. Natl. Acad. Sci. USA 98, 5122-5127 (2001).

- Harfe, B. D. & Jinks-Robertson, S. Sequence composition and context effects on the generation and repair of frameshift intermediates in mononucleotide runs in Saccharomyces cerevisiae. *Genetics* 156, 571-578 (2000).
- Tran, H. T., Gordenin, D. A. & Resnick, M. A. The 3'->5' exonucleases of DNA polymerase δ and ε and the 5'-3' exonuclease Exo1 have major roles in postreplication mutation avoidance in *Saccharomyces cerevisiae. Mol. Cell. Biol.* 19, 2000-2007 (1999).
- Gary, R. et al. A novel role in DNA metabolism for the binding of *Fen1/Rad27* to PCNA and implications for genetic risk. *Mol. Cell. Biol.* 19, 5373-5382 (1999).

Supplementary Note B.

STUDIES WITH HUMAN CELLS

Since MMR is conserved in eukaryotes, it is possible that chronic exposure to low, biologically relevant levels of cadmium may also inhibit MMR in human cells. For example, low levels of cadmium $(0.2 - 2 \mu M)$ were recently reported to increase carcinogenic transformation frequency of a mouse embryonic cell line by non-lethal doses of N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)¹. Previously it was shown that mammalian cells lacking MMR are able to tolerate MNNG and other alkylating agents by avoiding "futile cycles of repair" or by preventing apoptosis. As a result MNNG-induced mutagenesis in MMR deficient cells is greatly increased (reviewed in ²). We suggest that this might be due to inhibition of MMR by cadmium, thereby increasing both MNNG tolerance and mutagenesis, which would increase the likelihood of mutations and cell transformation. In order to evaluate possible effects of cadmium on MMR in human cells we examined its impact on microsatellite stability in two MMR-proficient human cells lines exposed to sub-lethal concentrations of 0.2 and 1 µM cadmium for 3 weeks (approximately 25 doublings). To detect short deletion/insertion events, variations in the size of mononucleotide repeat BAT26 were evaluated by small-pool PCR using an approach similar to that described by³. Cadmium exposure resulted in a small, but statistically significant increase in the frequency of mutant alleles (data not shown). However, we did not detect any changes in the size of BAT26 using standard, large-pool PCR of DNAs from clones derived from subsets of the cell populations treated with 1 μ M of cadmium (data not shown). The absence of a strong increase, as found for yeast, may reflect biological features of the cell lines used. The difference in results obtained with

5

the two techniques might be due to a higher sensitivity of small-pool PCR in detecting microsatellite changes in the fraction of cells with inhibited MMR, especially since the increase found with small-pool PCR is small. We suggest that more extensive studies with several cell lines will be required to determine the effect of cadmium on microsatellite instability in human cells.

References for Supplementary Note B.

- Fang, M. Z., Kim, D. Y., Lee, H. W. & Cho, M. H. Improvement of in vitro twostage transformation assay and determination of the promotional effect of cadmium. *Toxicol. In Vitro* 15, 225-231 (2001).
- Karran, P. Mechanisms of tolerance to DNA damaging therapeutic drugs. *Carcinogenesis* 22, 1931-1937 (2001).
- Bacon, A. L., Farrington, S. M. & Dunlop, M. G. Mutation frequency in coding and non-coding repeat sequences in mismatch repair deficient cells derived from normal human tissue. *Oncogene* 20, 7464-7471 (2001).

Supplementary Figure 1

Jin et al.



Spot-test of mutagenesis caused by divalent metal ions in a yeast A14 homonucleotide run allele *lys2-A*₁₄. Spot-tests were performed as described in Supplementary Note A. 200 μ l of a solution was added onto the circular filter at the center of the plate. Salt concentrations were chosen that caused growth inhibition in the vicinity of the filter: CdCl₂ - 12.5 mM, CoCl₂ - 250 mM; CuSO₄ - 375 mM, MnCl₂ - 500 mM; NiSO₄ - 500 mM; ZnSO₄ - 500 mM. Each revertant colony corresponds to a spontaneous or induced mutant.

Supplementary Figure 2

Jin et al.



Spot-tests of mutagenesis in *lys2-A*₁₄ microsatellite by agents causing oxidative damage. Spot-tests were performed as described in Supplementary Note A. 200 μ l of the following solutions were applied: CdCl₂ – 12.5 mM; H₂O₂ – 4.4 M; paraquat – 500 mM; t-BOOH (tert-butyl hydroperoxide) – 200 mM; FeCl₃ – 500mM. (Note: negative control (H₂O) and positive control (CdCl₂) are represented by images of the same plates as on Supplementary Fig. 1.

Supplementary Table 1. Effects of chronic exposure of yeast to CdCl₂ on the mutability of specific reporters, viability and formation of petite mutants.

					Mutation in the rep	orters		Petite mu	utants (%)	
Strain	Reporter	CdCl ₂ (µM)	Fold increase over untreated	Rate (median)	95% CI for rate	Frequency (median)	95% CI for frequency	Median	95% CI	Viability (%)
		0	1.0	3.6E-07	2.8E-07 - 6.1E-07	1.2E-06	7.9E-07 - 2.5E-06	2.8	2.4 - 4.3	100
		0.5	11	3.9E-06	1.8E-06 - 9.2E-06	2.4E-05	7.7E-06 - 6.4E-05	2.3	1.5 - 3.3	87
	lys2-A ₁₄	1	84	3.0E-05	2.3E-05 - 4.0E-05	2.3E-04	1.7E-04 - 3.4E-04	2.6	1.9 - 4.4	90
		3	1094	3.9E-04	3.2E-04 - 5.2E-04	4.0E-03	3.3E-03 - 5.2E-03	85	79 - 91	78
		5	2186	7.8E-04	6.2E-04 - 9.1E-04	7.9E-03	6.1E-03 - 9.1E-03	92	83 - 93	65
		0	1.0	1.2E-08	3.9E-09 - 2.8E-08	1.2E-08	3.9E-09 - 2.8E-08			
WT 414		0.5	2.7	3.2E-08	1.9E-08 - 5.1E-08	1.3E-08	3.2E-08 - 1.3E-07			
/E124)	his7-2	1	10	1.2E-07	9.8E-08 - 1.5E-07	2.2E-08	3.8E-08 - 4.7E-07			
(E134)		3	17	2.0E-07	1.2E-07 - 2.8E-07	5.1E-07	2.4E-07 - 8.0E-07			
		5	48	5.7E-07	2.5E-07 - 1.4E-06	1.6E-06	5.6E-07 - 4.5E-06		NI/A	
									10/0	
		0	1.0	3.8E-07	3.5E-07 - 1.9E-06	1.0E-06	8.5E-07 - 7.7E-06			
		0.5	1.1	4.2E-07	2.6E-07 - 5.6E-07	1.1E-06	5.7E-07 - 1.7E-06			
	CAN1	1	1.4	5.5E-07	2.5E-07 - 8.4E-07	1.3E-06	5.5E-07 - 2.5E-06			
		3	4.5	1.7E-06	8.3E-07 - 2.4E-06	6.1E-06	2.4E-06 - 9.1E-06			
		5	60	2.3E-05	2.4E-06 - 6.1E-05	9.7E-05	7.6E-06 - 2.5E-04			

I I					Mutation in the rep	orters		Petite mu	itants (%)	
Strain R	Reporter	CdCl ₂ (μM)	Fold increase over untreated	Rate (median)	95% CI for rate	Frequency (median)	95% CI for frequency	Median	95% CI	Viability (%)
		0	1.0	1.5E-07	9.2E-08 - 1.3E-06	4.2E-07	2.3E-07 - 6.8E-06	3.3	1.9 - 5.2	100
		0.5	0.94	1.4E-07	7.5E-08 - 2.2E-07	3.8E-07	1.8E-07 - 7.4E-07	4.2	2.1 - 4.5	108
l)	ys2-A ₁₂	1	4.3	6.4E-07	1.4E-07 - 1.6E-06	2.7E-06	3.9E-07 - 8.0E-06	3.3	2.9 - 6.6	108
	[3	90	1.3E-05	8.9E-06 - 3.1E-05	9.3E-05	6.1E-05 - 2.4E-04	86	79 - 94	77
		5	196	2.9E-05	1.9E-05 - 3.4E-05	2.1E-04	1.3E-04 - 2.4E-04	91	83 - 98	65
		0	1.0	2.8E-09	8.5E-11 - 1.6E-08	2.8E-09	8.5E-11 - 1.6E-08			
WT 412	[0.5	14	4.1E-08	2.2E-08 - 6.8E-08	1.7E-08	1.5E-08 - 1.6E-07			
(E133)	his7-2	1	23	6.6E-08	3.7E-08 - 7.9E-08	1.3E-07	5.7E-08 - 1.8E-07			
(E133)	[3	78	2.2E-07	1.3E-07 - 6.1E-07	6.1E-07	3.2E-07 - 2.3E-06			
		5	163	4.6E-07	2.6E-07 - 1.1E-06	1.3E-06	5.4E-07 - 4.5E-06		NI/A	
									10/4	
		0	1.0	2.7E-07	1.4E-07 - 4.6E-07	9.4E-07	4.0E-07 - 1.8E-06			
		0.5	0.72	2.0E-07	1.3E-07 - 2.7E-07	6.2E-07	3.7E-07 - 8.6E-07			
	CAN1	1	1.8	5.1E-07	2.6E-07 - 1.1E-06	2.0E-06	8.6E-07 - 5.5E-06			
	[3	8.1	2.2E-06	1.2E-06 - 4.3E-06	1.1E-05	5.8E-06 - 2.5E-05			
		5	65	1.8E-05	5.4E-06 - 4.3E-05	1.2E-04	3.1E-05 - 3.1E-04			
		0	1.0	8.2E-08	4.8E-08 - 1.0E-07	2.1E-07	1.1E-07 - 2.7E-07	3.0	1.5 - 4.6	100
		0.5	3.7	3.1E-07	2.4E-07 - 4.3E-07	1.1E-06	7.6E-07 - 1.6E-06	3.1	1.3 - 10	76
l)	ys2-A ₁₀	1	89	7.3E-06	5.5E-06 - 8.5E-06	4.9E-05	3.6E-05 - 5.9E-05	2.6	1.5 - 4.9	79
		3	616	5.0E-05	4.3E-05 - 8.0E-05	4.1E-04	3.4E-04 - 7.0E-04	87	85 - 93	79
		5	1637	1.3E-04	9.8E-05 - 1.8E-04	1.1E-03	7.9E-04 - 1.6E-03	94	88 - 100	75
		0	1.0	1.8E-08	8.6E-09 - 3.3E-08	1.8E-08	8.6E-09 - 3.3E-08			
WT, A10	[0.5	5.1	9.2E-08	6.3E-08 - 1.3E-07	9.2E-08	6.3E-08 - 1.3E-07			
(E26)	his7-2	1	3.7	6.7E-08	3.7E-08 - 1.1E-07	1.4E-07	4.9E-08 - 2.6E-07			
		3	9.1	1.6E-07	7.4E-08 - 5.4E-07	4.1E-07	1.3E-07 - 1.9E-06			
	I	5	23	4.2E-07	3.4E-07 - 6.5E-07	1.0E-06	7.4E-07 - 1.9E-06		N/A	
	ı									
		0	1.0	2.6E-07	2.3E-07 - 4.0E-07	1.0E-06	7.8E-07 - 1.6E-06			
	CAN14	0.5	1.6	4.1E-07	2.6E-07 - 1.0E-06	1.5E-06	8.3E-07 - 4.7E-06			
	CANT	1	1.5	3.9E-07	2.0E-07 - 5.2E-07	1.4E-06	6.7E-07 - 2.0E-06			
		3	5.7	1.5E-06	1.1E-06 - 5.7E-06	7.0E-06	4.9E-06 - 3.4E-05			

					Mutation in the rep	orters		Petite mu	utants (%)	
Strain	Reporter	CdCl₂ (μM)	Fold increase over untreated	Rate (median)	95% CI for rate	Frequency (median)	95% CI for frequency	Median	95% CI	Viability (%)
		0	1.0	4.6E-07	4.2E-07 - 6.6E-07	1.8E-06	1.7E-06 - 2.6E-06	1.7	1.0 - 2.3	100
		0.5	2.8	1.3E-06	5.0E-07 - 4.4E-06	6.3E-06	2.1E-06 - 2.7E-05	1.8	0.41 - 2.3	123
WT-SIR 10C		1	7.9	3.6E-06	2.7E-06 - 5.6E-06	2.1E-05	1.5E-05 - 3.5E-05	1.6	1.0 - 3.1	137
(SIR038)	lys2-10G	3	160	7.3E-05	5.5E-05 - 8.6E-05	6.4E-04	4.6E-04 - 7.3E-04	2.1	0.64 - 2.7	124
(001(000)		5	326	1.5E-04	1.0E-04 - 1.8E-04	1.3E-03	8.6E-04 - 1.7E-03	4.0	2.2 - 6.5	105
		10	451	2.1E-04	1.7E-04 - 7.6E-04	1.8E-03	1.4E-03 - 7.1E-03	8.3	3.8 - 18	61
		20	934	4.3E-04	3.2E-04 - 6.2E-04	3.7E-03	2.7E-03 - 5.3E-03	28	19 - 33	27
									_	
		0	1.0	7.0E-08	4.2E-08 - 1.1E-07	1.4E-07	5.4E-08 - 2.7E-07	1.1	0.8 - 1.9	100
		1	2.1	1.4E-07	8.0E-08 - 2.4E-07	1.4E-07	1.5E-07 - 3.3E-07	1.1	0.0 - 1.3	105
WT-SIR 10A		1	3.3	2.3E-07	7.4E-08 - 4.4E-07	7.2E-07	1.3E-07 - 1.7E-06	1.0	0.42 - 2.6	112
(SJR939)	lys2-10A	3	80	5.5E-06	4.3E-06 - 7.1E-06	3.3E-05	2.5E-05 - 4.6E-05	2.8	1.5 - 4.8	110
(001(000))		5	141	9.8E-06	7.8E-06 - 1.3E-05	7.2E-05	5.1E-05 - 8.2E-05	3.7	1.9 - 6.3	95
		10	398	2.8E-05	1.6E-05 - 3.6E-05	1.8E-04	9.0E-05 - 2.5E-04	12	2.6 - 18	73
		20	856	6.0E-05	4.5E-05 - 6.1E-05	4.0E-04	3.1E-04 - 4.3E-04	22	16 - 40	85
		0	1.0	3.9E-07	3.6E-07 - 6.7E-07	1.3E-06	1.1E-06 - 2.9E-06	1.5	0.0 - 1.7	100
		0.5	1.7	6.6E-07	2.8E-07 - 7.2E-07	2.6E-06	9.7E-07 - 2.7E-06	0.67	0.0 - 1.8	86
WT-SIR 10T		1	2.0	7.9E-07	4.5E-07 - 1.3E-06	3.2E-06	1.5E-06 - 5.3E-06	0.38	0.0 - 2.2	96
(\$ 18980)	lys2-10T	3	29	1.1E-05	8.0E-06 - 1.5E-05	7.4E-05	4.9E-05 - 1.0E-04	1.6	0.0 - 3.4	90
(05(300)		5	82	3.2E-05	2.8E-05 - 3.6E-05	2.3E-04	1.9E-04 - 2.8E-04	2.7	0.9 - 3.9	79
		10	162	6.3E-05	4.2E-05 - 1.3E-04	4.7E-04	3.0E-04 - 1.0E-03	9.8	5.4 - 14	78
		20	262	1.0E-04	7.9E-05 - 2.1E-04	7.5E-04	6.0E-04 - 1.8E-03	28	16 - 39	64
		0	1.0	3.3E-07	2.1E-07 - 4.8E-07	1.1E-06	5.0E-07 - 1.7E-06	2.5	1.3 - 2.9	100
		0.5	2.4	7.9E-07	3.1E-07 - 9.3E-07	3.4E-06	8.8E-07 - 3.9E-06	1.1	0.0 - 3.1	103
WT-S.IR 10C		1	3.0	1.0E-06	4.7E-07 - 1.3E-06	4.5E-06	1.7E-06 - 5.6E-06	1.7	0.47 - 2.3	103
(SJR981)	lys2-10C	3	77	2.6E-05	1.8E-05 - 3.2E-05	1.9E-04	1.3E-04 - 2.5E-04	2.2	0.80 - 3.9	98
(05(301)		5	229	7.6E-05	4.3E-05 - 1.5E-04	6.1E-04	3.4E-04 - 1.2E-03	3.8	1.9 - 12	100
		10	676	2.3E-04	1.6E-04 - 6.0E-04	1.9E-03	1.2E-03 - 5.3E-03	14	12.0 - 17	90
		20	1128	3.8E-04	2.4E-04 - 4.5E-04	3.3E-03	2.0E-03 - 3.9E-03	22	17 - 35	24

					Mutation in the rep	orters		Petite m	utants (%)	
Strain	Reporter	CdCl ₂ (µM)	Fold increase over untreated	Rate (median)	95% CI for rate	Frequency (median)	95% CI for frequency	Median	95% CI	Viability (%)
		0	1.0	1.4E-03	9.5E-04 - 1.7E-03	1.2E-02	7.8E-03 - 1.6E-02	6.1	3.9 - 8.1	100
		0.5	0.9	1.2E-03	9.8E-04 - 1.4E-03	1.1E-02	7.4E-03 - 1.3E-02	7.0	3.4 - 15	77
	lys2-A ₁₄	1	1.1	1.4E-03	9.9E-04 - 2.6E-03	1.2E-02	7.8E-03 - 2.6E-02	11	7.0 - 21	87
		3	1.2	1.6E-03	8.9E-04 - 2.7E-03	1.2E-02	7.8E-03 - 2.1E-02	99	95 - 100	73
		5	1.1	1.4E-03	1.1E-03 - 2.0E-03	1.1E-02	7.1E-03 - 1.5E-02	85	41 - 100	67
					-					
		0	1.0	3.3E-06	1.4E-06 - 7.1E-06	1.6E-05	5.8E-06 - 3.6E-05			
msh2, A14		0.5	2.0	6.7E-06	3.2E-06 - 1.1E-05	3.6E-05	1.5E-05 - 6.2E-05			
(YH1026 &	his7-2	1	1.8	5.9E-06	7.0E-07 - 1.4E-05	3.0E-05	2.0E-06 - 8.1E-05			
YH1027)		3	1.5	4.8E-06	7.8E-07 - 8.6E-06	2.1E-05	2.2E-06 - 4.1E-05			
		5	2.3	7.5E-06	3.6E-06 - 1.1E-05	3.3E-05	1.4E-05 - 5.3E-05		N/A	
		0	1.0	1.9E-05	4.8E-06 - 1.1E-04	1.2E-04	2.5E-05 - 9.4E-04			
		0.5	0.33	6.2E-06	4.3E-06 - 8.9E-06	3.3E-05	2.1E-05 - 5.0E-05			
	CAN1	1	0.57	1.1E-05	6.4E-06 - 3.4E-04	5.6E-05	3.5E-05 - 3.1E-03			
		3	0.64	1.2E-05	8.2E-06 - 8.2E-05	6.2E-05	3.8E-05 - 5.8E-04			
		5	0.57	1.1E-05	3.0E-06 - 2.0E-04	5.1E-05	1.2E-05 - 1.4E-03			
		0	1.0	2.4E-06	1.3E-06 - 4.2E-06	1.3E-05	6.8E-06 - 2.5E-05	2.1	0.46 - 2.7	100
		0.5	3.0	7.2E-06	3.8E-06 - 1.3E-05	4.5E-05	2.2E-05 - 9.1E-05	2.2	1.5 - 4.8	107
	lysz-A ₁₄	1	25	6.0E-05	5.0E-05 - 7.8E-05	4.8E-04	4.0E-04 - 6.4E-04	3.7	0.84 - 6.3	105
		3	233	5.5E-04	4.4E-04 - 8.0E-04	5.5E-03	4.4E-03 - 8.4E-03	88	80 - 92	92
		5	515	1.2E-03	1.0E-03 - 1.8E-03	1.2E-02	1.0E-02 - 1.8E-02	93	84 - 100	96
			4.0			0.05.07	0.05.00.005.00			
		0	1.0	9.0E-08	4.6E-08 - 7.2E-07	2.0E-07	6.6E-08 - 3.2E-06			
msn3, A14	hi=7.0	0.5	0.94	8.5E-08	4.3E-08 - 1.5E-07	1.7E-07	6.2E-08 - 3.6E-07			
(TH1020 & VH1020)	nis/-2	1	1.3	1.2E-07	8.1E-08 - 1.8E-07	2.2E-07	1.3E-07 - 3.8E-07			
YH1029)		3	3.3	2.9E-07	1.4E-07 - 5.4E-07	7.2E-07	2.5E-07 - 1.7E-06			
		5	0.0	5.8E-07	3.2E-07 - 2.4E-06	1.3E-06	5.3E-07 - 9.0E-06		N/A	
		0	10	7.6E-07	46E-07 - 10E-06	3 3E-06	175-06-115-05			
		0.5	0.67	5.1E-07	4.02-07 - 1.92-00	1.9E-06	1.72-06 - 2.55-06			
1	CAN1	1	1.1	8.3E-07	6 1E-07 - 2 9E-06	3.1E-06	2.5E-06 - 1.5E-05			
	CAN	2	4.4	3.4E-06	2.25-06-4.45-04	1.6E-05	1.0E-05 - 1.0E-03			
		5	4.4	3.4E-06	1 1E-05 - 2 6E-04	3.2E-04	6 0E-05 - 2 2E-03			
		5	65	4.9E-05	1.1E-05 - 2.0E-04	3.2E-04	0.0E-05 - 2.2E-03			

					Mutation in the rep	orters		Petite m	utants (%)		
Strain	Reporter	CdCl ₂ (μM)	Fold increase over untreated	Rate (median)	95% CI for rate	Frequency (median)	95% CI for frequency	Median	95% CI	Viability (%)	
		0	1.0	6.5E-05	6.1E-05 - 9.6E-05	5.0E-04	4.6E-04 - 7.5E-04	1.6	0.30 - 2.2	100	
		0.5	1.3	8.2E-05	5.8E-05 - 2.5E-04	6.5E-04	4.4E-04 - 2.3E-03	1.3	0.39 - 4.0	101	
	lys2-A ₁₄	1	3.2	2.1E-04	9.7E-05 - 1.7E-03	1.8E-03	8.0E-04 - 1.9E-02	2.7	0.30 - 4.6	95	
		3	11	6.8E-04	3.8E-04 - 8.8E-04	6.5E-03	3.4E-03 - 8.8E-03	73	68 - 79	89	
		5	12	7.9E-04	6.1E-04 - 1.1E-03	7.2E-03	5.4E-03 - 1.1E-02	96	92 - 98	85	
		0	1.0	1.6E-07	1.2E-07 - 3.8E-07	2.7E-07	1.6E-07 - 1.0E-06				
msh6, A14		0.5	1.5	2.4E-07	1.0E-07 - 4.6E-07	5.3E-07	9.7E-08 - 1.3E-06				
(YH1030 &	his7-2	1	0.7	1.1E-07	5.0E-08 - 8.2E-07	1.4E-07	3.3E-08 - 2.5E-06				
YH1031)		3	1.8	2.9E-07	1.8E-07 - 3.8E-07	5.5E-07	2.4E-07 - 8.3E-07				
		5	3.8	6.0E-07	2.9E-07 - 2.2E-06	1.2E-06	4.0E-07 - 6.5E-06	N/A			
									19/25		
	CAN1	0	1.0	3.7E-06	3.3E-06 - 4.2E-06	1.8E-05	1.5E-05 - 2.0E-05				
		0.5	1.0	3.7E-06	2.9E-06 - 1.6E-05	1.8E-05	1.4E-05 - 9.7E-05				
		1	1.4	5.1E-06	2.5E-06 - 6.0E-05	2.6E-05	1.2E-05 - 4.6E-04				
		3	1.2	4.5E-06	2.5E-06 - 6.8E-06	2.1E-05	1.0E-05 - 3.3E-05				
		5	6.2	2.3E-05	4.8E-06 - 6.7E-05	2.3E-05	4.8E-06 - 6.7E-05				
		0	1.0	6.0E-05	8.3E-06 - 2.2E-04	4.0E-04	3.1E-05 - 1.6E-03	0.0	0.0 - 2.5	100	
		0.5	4.6	2.8E-04	3.6E-05 - 8.8E-04	2.1E-03	2.2E-04 - 7.5E-03	2.3	0.0 - 17	95	
	lys2-A ₁₄	1	34	2.0E-03	1.4E-03 - 2.3E-03	1.8E-02	1.3E-02 - 2.1E-02	21	0.0 - 29	95	
2n nol3-01		3	53	3.2E-03	2.3E-03 - 4.4E-03	2.8E-02	2.1E-02 - 3.7E-02	31	7.0 - 41	88	
211, p013-01, A14		5	70	4.2E-03	2.4E-03 - 1.0E-02	3.6E-02	2.1E-02 - 9.2E-02	42	31 - 72	80	
VH086)		0	1.0	1.7E-05	9.5E-06 - 5.7E-05	9.2E-05	4.4E-05 - 3.6E-04				
11300)		1	2.6	4.5E-05	1.1E-05 - 1.2E-04	2.4E-04	4.6E-05 - 6.8E-04		N/A		
	his7-2	1	8.7	1.5E-04	1.2E-04 - 2.2E-04	9.7E-04	7.1E-04 - 1.4E-03		19//5		
		3	8.0	1.4E-04	6.0E-05 - 1.9E-04	7.6E-04	2.4E-04 - 1.1E-03				
		5	14	2.4E-04	8.9E-05 - 3.0E-04	1.3E-03	4.8E-04 - 2.0E-03				

					Mutation in the rep	orters		Petite m	utants (%)	
Strain	Reporter	CdCl ₂ (µM)	Fold increase over untreated	Rate (median)	95% CI for rate	Frequency (median)	95% CI for frequency	Median	95% CI	Viability (%)
		0	1.0	3.6E-07	2.1E-07 - 6.9E-07	1.2E-06	6.1E-07 - 2.7E-06	0.0	0.0 - 1.1	100
		0.5	6	2.3E-06	1.3E-06 - 6.2E-06	1.2E-05	6.0E-06 -3.8E-05	0.0	0.0 - 1.1	98
	lys2-A ₁₄	1	78	2.8E-05	1.4E-05 - 6.4E-05	2.2E-04	1.1E-04 - 5.6E-04	0.53	0.50 - 0.95	93
		3	1450	5.2E-04	3.9E-04 - 5.8E-04	5.4E-03	4.1E-03 - 6.2E-03	18	11.0 - 21	87
2n, WT, A14		5	2104	7.5E-04	6.1E-04 - 9.5E-04	7.9E-03	6.3E-03 - 1.0E-02	91	89 - 94	73
(YH990 &										
YH991)		0	1.0	3.6E-08	1.2E-08 - 1.5E-07	8.1E-08	1.2E-08 - 4.6E-07			
		0.5	2.2	7.9E-08	2.9E-08 - 2.5E-07	2.1E-07	5.8E-08 - 9.8E-07	7 N/A		
	his7-2	1	3.5	1.2E-07	5.7E-08 - 2.5E-07	4.1E-07	1.4E-07 - 1.0E-06			
		3	33	1.2E-06	5.5E-07 - 2.0E-06	6.1E-06	2.5E-06 - 1.1E-05			
		5	24	8.6E-07	4.1E-07 - 2.5E-06	3.5E-06	1.5E-06 - 1.3E-05			
								-		
	lys2-A ₁₄	0	1.0	3.9E-07	3.2E-07 - 4.7E-07	1.5E-06	1.2E-06 - 1.9E-06	2.6	1.8 - 3.6	100
		0.5	49	1.9E-05	1.5E-05 - 2.6E-05	1.6E-04	1.1E-04 - 2.1E-04	2.0	1.4 - 3.5	92
		1	865	3.4E-04	1.9E-04 - 6.4E-04	3.6E-03	2.0E-03 - 7.3E-03	8.3	4.9 - 13	95
		3	2578	1.0E-03	7.6E-04 - 1.6E-03	1.1E-02	8.4E-03 - 1.9E-02	92	90 - 95	94
		5	4950	2.0E-03	1.2E-03 - 2.4E-03	2.3E-02	1.3E-02 - 2.9E-02	92	76 - 95	85
		0	1	4.4E-08	2.7E-08 - 6.2E-08	1.1E-07	5.4E-08 - 1.7E-07			
pol2-4, A14		0.5	9	3.9E-07	1.1E-07 - 1.3E-06	1.2E-06	1.7E-07 - 5.2E-06			
(YH1052 &	his7-2	1	190	8.4E-06	1.8E-06 - 2.6E-05	5.2E-05	8.7E-06 - 1.9E-04			
YH1053)		3	279	1.2E-05	8.1E-06 - 6.8E-05	7.2E-05	4.6E-05 - 5.2E-04			
		5	230	1.0E-05	7.2E-06 - 3.3E-05	5.4E-05	3.8E-05 - 2.1E-04		N/A	
						_			19/0	
		0	1.0	1.3E-06	8.6E-07 - 3.8E-06	5.9E-06	3.5E-06 - 2.1E-05			
		0.5	3.8	5.1E-06	3.3E-06 - 7.5E-05	2.8E-05	1.7E-05 - 6.3E-04			
	CAN1	1	30	4.1E-05	1.8E-05 - 4.9E-05	3.1E-04	1.2E-04 - 3.8E-04			
		3	60	8.0E-05	2.0E-05 - 1.6E-04	6.2E-04	1.3E-04 - 1.3E-03			
		5	133	1.8E-04	1.5E-04 - 4.9E-04	1.5E-03	1.2E-03 - 4.5E-03			

Supplementary Table 2. Mutation rates in the yeast $lys2-A_{14}$ microsatellite during chronic exposure to hydrogen peroxide and paraquat.

				Mutation in lys2-/	A ₁₄		Petite m	utants (%)	
Agent	Concentration (mM)	fold increase over untreated	Rate (median)	95% CI for rate	Frequency (median)	95% CI for frequency	Median	95% CI	Viability (%)
Control	0	1.0	3.1E-07	2.2E-07 - 4.3E-07	8.0E-07	5.6E-07 - 1.3E-06	4.2	2.3 - 6.0	100
	0.5	1.3	4.1E-07	2.3E-07 - 7.7E-07	1.1E-06	5.2E-07 - 2.7E-06	16	6.3 - 23	73
H ₂ 0 ₂	1	1.2	3.6E-07	2.6E-07 - 1.2E-06	1.0E-06	6.5E-07 - 4.9E-06	4.3	2.5 - 5.4	10
	1.5	0.9	2.8E-07	1.8E-07 - 2.7E-06	7.5E-07	4.5E-07 - 1.3E-05	3.4	2.3 - 4.6	1.1
				-					
	0.05	1.0	3.0E-07	1.6E-07 - 4.2E-07	8.6E-07	3.5E-07 - 1.2E-06	0.87	0.0 - 3.4	108
	0.1	0.6	1.9E-07	1.2E-07 - 2.8E-07	3.9E-07	3.1E-07 - 7.4E-07	1.8	0.0 - 3.2	105
Paraquat	0.5	1.2	3.8E-07	2.1E-07 - 1.4E-06	9.8E-07	5.5E-07 - 5.2E-06	69	47.1 - 88	100 very slow growth

Colonies were growing significantly slower in the presence of 0.5 mM of paraquat (not shown), while less than 1% cells formed

colonies on the media with 1mM of paraquat, indicating biological effect in the tested range of concentrations.

				Recombination	on		Petite m	utants (%)	
Strain	CdCl ₂ (µM)	Fold increase over untreated	Rate (median)	95% CI for rate	Frequency (median)	95% CI for frequency	Median	95% CI	Viability (%)
	0	1.0	1.0E-07	7.5E-08 - 1.4E-07	3.1E-07	2.1E-07 - 4.2E-07	2.9	2.1 - 5.2	100
Interchromosomal	0.5	1.3	1.3E-07	7.5E-08 - 1.8E-07	3.5E-07	1.9E-07 - 5.3E-07	2.4	1.7 - 4.9	100
recombination	1	1.4	1.5E-07	9.6E-08 - 3.7E-07	4.1E-07	2.4E-07 - 1.3E-06	4.3	2.8 - 4.9	103
(ALE100 & ALE101)	3	2.8	2.9E-07	1.9E-07 - 2.3E-06	9.0E-07	5.5E-07 - 1.1E-05	94	75 - 97	73
	5	3.6	3.8E-07	2.6E-07 - 9.2E-06	1.0E-06	6.6E-07 - 5.6E-05	94	88 - 96	73
	0	1.0	8.4E-06	4.4E-06 - 1.7E-05	4.2E-05	2.1E-05 - 9.7E-05			100
Intrachromosomal	0.5	1.0	8.0E-06	6.0E-06 - 1.4E-05	3.8E-05	2.7E-05 - 7.6E-05			96
recombination	1	1.0	8.0E-06	5.3E-06 - 2.1E-05	3.8E-05	2.3E-05 - 1.2E-04	1	D	89
(ALE1000 & ALE1001)	3	1.0	8.7E-06	4.0E-06 - 1.7E-05	4.3E-05	1.8E-05 - 8.6E-05			86
	5	1.1	9.2E-06	4.0E-06 - 5.9E-05	3.3E-05	1.3E-05 - 1.9E-04			90

Supplementary Table 3. Effects of chronic exposure of yeast to CdCl₂ on recombination in yeast.

		wild	type			pol	12-4	
	0 μM	CdCl ₂ *	5 μN	A CdCl ₂	0 μN	A CdCl ₂	5 µN	A CdCl ₂
	mutation	occurrence	mutation	occurrence	mutation	occurrence	mutation	occurrence
Deres	С→А	4/20	С→А	2/24	C→G	1	С→А	1
Base	С→Т	2/20	G→T	2/24	C→T	1	C→T	3
substitution	C→G	1/20	G→A	1/24	G→A	2	G→T	5
	G→A	4/20			G→T	6	G→A	4
	G→T	3/20		total	А→Т	4	A→G	1
	A→G	1/20		5/24 (21%)				
	Т→А	1/20				total 14/18		total 14/30
		total				(78%)		(47%)
		16/20				(7070)		(1770)
		(80%)						
E 1:0	$T_4 \rightarrow T_3$	1/20	$C_3 \rightarrow C_2$	4	A₄→A₃	1	$T_6 \rightarrow T_7$	5
Frameshift	$T_3 \rightarrow T_2$	1/20	$G_4 \rightarrow G_3$	1	$T_6 \rightarrow T_7$	2	$T_5 \rightarrow T_6$	2
			$A_6 \rightarrow A_5$	6			$T_3 \rightarrow T_4$	1
			$A_5 \rightarrow A_4$	1			$A_4 \rightarrow A_5$	2
		total $2/20$ (10%)	$A_1 \rightarrow A_0$	1		total $\frac{3}{18}(17\%)$		
		2/20 (1070)	$T_6 \rightarrow T_7$	2		5/18 (1770)	$T_6 \rightarrow T_5$	2
			$T_4 \rightarrow T_3$	4			$A_6 \rightarrow A_5$	3
							$A_5 \rightarrow A_4$	1
				total				
				19/24				total
				(79%)				16/30 (53%)
Deletion ^{‡‡}	Δ_{1324} - 1339 (16, 8)	1/20 (5%)		0/24 (0%)	Δ ₂₇₆ - 302 (27, 8)	1 1/18 (0.06%)		0/30 (0%)
Complex	TTCTC →CTCT	1/20 (5%)		0/24 (0%)		0/18 (0%)		0/30 (0%)

Supplementary Table 4 Spectrum of *can1* mutations.

Nucleotide coordinates of the wild-type *CAN1* gene are used with the A of the ATG as nucleotide 1. Deletion mutations are designated by $\Delta_{x-y}(a, b)$, where x is the nucleotide coordinate of the first nucleotide of the wild-type sequence that is deleted, and y is the nucleotide coordinate of the last nucleotide that is deleted; *a* - length (nt) of the deletion; *b* - length (nt) of the associated short repeat sequences. Data for 0 µM of CdCl₂ are from Jin *et al. Proc. Natl. Acad. Sci. USA* 98, 5122-5127 (2001)